

## **€15.5 million EUROPRISE to drive novel approaches to HIV prevention**

A €15.5 million grant from the European Commission will bring together HIV/AIDS researchers at 32 institutions - including universities, governmental research institutes and pharmaceutical industries - in 10 countries to prevent the spread of AIDS. The award holds out the promise of the most important advance yet in scientific efforts at a European-wide level in HIV-1 prevention and represents another resounding endorsement of the high commitment to HIV/AIDS prevention research in Europe.

The European HIV Enterprise (EUROPRISE) consortium will promote an integrated program of research, coordinating a wide portfolio of activities encompassing the whole pipeline of vaccine and microbicide development from discovery through to early clinical trials for the next five years. Together these projects represent more than 150 institutions from 22 countries including two major pharmaceutical companies (Novartis and GlaxoSmith Kline). This unique approach places the network at the international forefront of understanding the interface between these two technologies (microbicides and vaccines), pursuing a critical path to the development of effective HIV-1 prevention strategies.

### **The urgent need for HIV prevention**

The UNAIDS/WHO estimates that at the end of 2004, forty million people globally were living with HIV, of which 740,000 were in Western Europe and 25 million were in Sub-Saharan Africa. Globally, there are 14,000 new HIV infections per day, 80% of which are now heterosexual, and 95% of which are in developing countries. While public health programmes encouraging the use of condoms have achieved results in reducing HIV infection rates, it is clear that additional preventative strategies are needed. Although therapeutics for HIV/AIDS continue to improve, ultimately the development of safe and effective strategies of blocking and preventing HIV transmission will be key to combating this pandemic.



## **Why Microbicides and Vaccines?**

It is currently understood that conventional vaccine approaches fail to induce sufficient mucosal response and immunological memory to provide protection against the diversity of circulating HIV strains. In contrast, while it may be technically easier to develop microbicides (vaginal formulation, gels or creams) that prevent HIV transmission, their duration of protection is likely to be short lived and their efficacy will be critically dependent upon consistent use. In the past, both fields have been slow to work together in the development of products that provide multiple levels of protection. This network is focused on the premise that microbicides and vaccines that target multiple stages of mucosal transmission will have the best chance of success. Since both target the same processes there is clear synergy between the two fields.

## **What is the timescale and who is involved**

Robin Shattock and St George's, University of London will coordinate the consortium, together with the scientific coordination of Hans Wigzell from the Karolinska Institute (Stockholm) and Rino Rappuoli, the coordinator for HIV vaccines, from Novartis (Siena). In addition to UK, Italy and Sweden, the other countries involved are Austria, Belgium, France, Germany, Netherlands, Russia and Spain (for in country contacts please see the attached sheet).

This is a five-year project that will start on January 1<sup>st</sup> 2007 and is designed to take this approach into early human trials.

### **Notes to Editors**

For further information please contact ([Add country contact here](#))

Or

Natasha Polyanskaya, Europrise Project Manager, Telephone +44 (0)1980620130  
email: [npolyans@sgul.ac.uk](mailto:npolyans@sgul.ac.uk)

Primary participants contact details

Primary contact	Contact details
Dr R Shattock	Department of Cellular and Molecular Medicine, Cranmer Terrace, Tooting, London, SW17 ORE, UK. Phone: (0)2087255855, Fax (0)2087253487, email: <a href="mailto:shattock@sgul.ac.uk">shattock@sgul.ac.uk</a>
Dr H Wigzell	Karolinska Institutet, Karolinska University Hospital, Huddinge S-141 86 Stockholm Sweden 0046705760539 Hans Wigzell < <a href="mailto:Hans.Wigzell@ki.se">Hans.Wigzell@ki.se</a> >
Dr R Rappuoli	Novartis Vaccines and Diagnostics SrL. Italy Internet homepage <a href="http://www.novartis.com">www.novartis.com</a> Phone: +39 0577 243414 <a href="mailto:Rino.Rappuoli@chiron.com">Rino Rappuoli Rino_Rappuoli@chiron.com</a>
Prof D Medaglini	University of Siena Medical School, Department of Molecular Biology, Laboratory of Molecular Microbiology and Biotechnology (L.A.M.M.B.), Policlinico Le Scotte - Lotto 5° - Piano 1°, Viale Bracci, 53100 Siena, Italy. Tel: 0039-0577-233307, Fax: 0039-0577-233334, e-mail: <a href="mailto:medaglini@unisi.it">medaglini@unisi.it</a> □
Dr A Tagliabue	Alta srl, Via Fiorentina 1, 53100 Siena Tel. +39 0577 243508 Fax. +39 0577 278515 Email: <a href="mailto:Aldo_Tagliabue@chiron.com">Aldo_Tagliabue@chiron.com</a> >
Dr G Voss	GlaxoSmith Kline, Belgium Ph. +32-2-656 8243, fax +32-2-656 8113 Gerald Voss < <a href="mailto:gerald.voss@gskbio.com">gerald.voss@gskbio.com</a> >
Prof. H Katinger	Polymun Scientific, Polymun Scientific GmbH, Nussdorfer Laende 11, A-1190 Vienna, Austria Tel: +43 1 36006 6202/3 Fax: +43 1 36 97 615 Email: <a href="mailto:Polymun@iam.boku.ac.at">Polymun@iam.boku.ac.at</a> >
Prof. C Kelly	Department of Oral Immunology, King's College London Dental Institute, Floor 28 Guy's Tower, Guy's Hospital London SE1 9RT. UK Tel: 44 (0)20 7188 4379 (direct line) Fax: 44 (0)20 7188 4375 email: <a href="mailto:charles.kelly@kcl.ac.uk">charles.kelly@kcl.ac.uk</a>
Dr G Scala	Department of Biochemistry and Medical Biotechnology University Federico II, Via S. Pansini 5, 80131 Naples, ITALY. Tel: 39-081-746-3622 (office) Fax: 39-081-746 2685 E-mail: <a href="mailto:scala@dbbm.unina.it">scala@dbbm.unina.it</a>
Dr K Uberla	Department of Molecular and Medical Virology □ Ruhr-

	University Bochum □ Universitaetsstr. 150, D-44780 Bochum, Germany. Tel.: 49-234-3223189, Fax: 49-234-3214352, E-mail: klaus.ueberla@ruhr-uni-bochum.de
Dr H Holmes	National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK Email: <a href="mailto:hholmes@nibsc.ac.uk">hholmes@nibsc.ac.uk</a> , Tel: 0044 1707 641218 Fax: 0044 1707 641060 Programme EVA CFAR: <a href="http://www.nibsc.ac.uk/spotlight/aids.html">http://www.nibsc.ac.uk/spotlight/aids.html</a>
Prof R Weiss	Wohl Virion Centre, Division of Infection and Immunity University College London. Windeyer Building, 46 Cleveland Street. London W1T 4JF, UK Tel: +44 (0)20 7679 9554 Fax: +44 (0)20 7679 9555 email: <a href="mailto:r.weiss@ucl.ac.uk">r.weiss@ucl.ac.uk</a>
Prof F Gotch	Department of Immunology Imperial College London, Room 1.2.8, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK tel 0044 (0)2087468257 fax 0044 (0)2087465997 email <a href="mailto:f.gotch@imperial.ac.uk">f.gotch@imperial.ac.uk</a>
Dr V Jaspers	STD/HIV Research and Intervention Unit, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerpen, Belgium Phone: 00 323 2476296 email: <a href="mailto:VJaspers@itg.be">VJaspers@itg.be</a>
Dr S McCormack	MRC Clinical Trials Unit, 222 Euston Road London, NW1 2DA, UK Tel: 44 20 7670 4714 Fax: 44 20 7670 4815 Email: <a href="mailto:smc@ctu.mrc.ac.uk">smc@ctu.mrc.ac.uk</a>
Dr G Scarlatti	Viral Evolution and Transmission Unit, DIBIT - San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan - Italy Phone:+39 02 2643 4906 (dir) or 2821 (Assistant), Fax:+39 02 2643 4905 Email: <a href="mailto:scarlatti.gabriella@hsr.it">scarlatti.gabriella@hsr.it</a>
Dr R Le Grand	Service de neurovirologie / UMR E1, Paris XI, Commissariat à l'Energie Atomique, DSV/DRM, 18, route du Panorama, 92265, Fontenay-aux-Roses, Cedex, France Tel: +33-1-46 54 87 57 ou +33-1-46 54 73 74 Fax: +33-1-46 54 77 26 e-mail: <a href="mailto:roger.le-grand@cea.fr">roger.le-grand@cea.fr</a>
Dr C Lacey	GU/HIV Medicine, Hull York Medical School, University of York, Office Tel - (44)(0) 1904 725425 Email : <a href="mailto:Charles.Lacey@hyms.ac.uk">Charles.Lacey@hyms.ac.uk</a>

Dr Q Sattentau	<p>Quentin Sattentau □ Department of Pathology □ University of Oxford □ South Parks Road □ Oxford OX1 3RE, UK. Tel/Fax: +44 1865 275511 □ <a href="mailto:quentin.sattentau@path.ox.ac.uk">quentin.sattentau@path.ox.ac.uk</a></p>
Dr P La Colla	<p>Dept. of Biomedical Sciences and Technologies, Università di Cagliari, 09042 Monserrato (ITALY) Phone: +39-0706754148, Fax +39-0706754210, email <a href="mailto:placolla@unica.it">placolla@unica.it</a></p>
Dr Christiane Stahl-Hennig	<p>Deutsches Primatenzentrum GmbH Ph. +49-551-3851150, fax +49-551-3851184 Email: <a href="mailto:stahlh@dpz.gwdg.de">stahlh@dpz.gwdg.de</a></p>
Dr Fenyö	<p>Laboratory Medicine, Medical Faculty, Lund University, Po Box 223 62, Solvegatan 23, Lund, Sweden. Phone: +46 46 173275, Fax: +46 46 176033, email: <a href="mailto:Eva_Maria.Fenyö@med.lu.se">Eva_Maria.Fenyö@med.lu.se</a></p>
Dr F Tangy	<p>Unité des Virus Lents Institut Pasteur 28 rue du Dr Roux, 75015 Paris, France tel (33) 1 45 68 87 73, fax (33) 1 40 61 31 67 email : <a href="mailto:ftangy@pasteur.fr">ftangy@pasteur.fr</a></p>
Prof H Schuitemaker	<p>Department of Clinical Viro Immunology, Sanquin Research Phone: 31-20-5123317, email: <a href="mailto:h.schuitemaker@sanquin.nl">h.schuitemaker@sanquin.nl</a></p>
Prof R Najera Dr J Alcami	<p>Department of Viral Pathogenesis, National Center for Microbiology, Instituto de Salud Carlos III, Carretera de Majadahonda a Pozuelo, Km. 2, 28220 Majadahonda. Madrid. Tel.: 34-91-822-3910, Fax: 34-91-509-7014 e-mail: <a href="mailto:rafael.najera@isciii.es">rafael.najera@isciii.es</a>. Phone: +34 91 5097052 FAX: +34 91 5097919 <a href="mailto:ppalcami@isciii.es">ppalcami@isciii.es</a></p>
Dr D Zipeto	<p>Dept. of Mother and Child, Biology and Genetics, Faculty of Medicine; Laboratory of Molecular Biology, P. O. Box 37134, Stada Le Grazie 8, Verona, Italy Ph. +39-045-8027284, fax +39-045-8027180, <a href="mailto:donato.zipeto@univr.it">donato.zipeto@univr.it</a>.</p>
Dr S Norley	<p>Robert Koch-Institut Stephen Norley AIDS Immunopathogenesis and Vaccine Development Phone: +49 (0)30 4547 2380 Fax: +49 (0) 30 4547 2914 Email: <a href="mailto:NorleyS@rki.de">NorleyS@rki.de</a></p>
Prof. E Karamov	<p>Ivanovsky Institute of Virology, Russian Academy of Medical Science. Phone +7-095-1903048, fax +7-095-1902867, Email: <a href="mailto:karamov2004@yandex.ru">karamov2004@yandex.ru</a> and <a href="mailto:turgiev@ld.ru">turgiev@ld.ru</a></p>
Dr K Nihlmark	<p>Mabtech AB, Box 1233, SE-131 28 Nacka strand, Sweden Phone: +46 8 556 79809</p>



**St George's**  
University of London

	Fax: +46 8 716 27 01 Email: <a href="mailto:kopek@mabtech.com">kopek@mabtech.com</a> .
Nikos Dedes	European AIDS Treatment Group, rue Washington 40 (box 15), 1050 Brussels, Belgium Mobile: +30 6944 386560, Tel: +32 2 644 42 10 Fax: +32 2 644 33 07, <a href="http://www.eatg.org">www.eatg.org</a> . email: <a href="mailto:ndedes@hol.gr">ndedes@hol.gr</a>
Dr Christiane Moog,	EA3770, Laboratoire de Virologie, Universite Louis Pasteur, PO BOX 67000, 3 rue Koeberle, Strasbourg, France. Phone: 33390243742, Fax: 33390243723, Email: <a href="mailto:c.moog@viro-ulp.u-strasbg.fr">c.moog@viro-ulp.u-strasbg.fr</a>